Document:

ex102.htm

    
      ALLIANCE AGREEMENT
between USIS Commercial Services, Inc. and Labwire, Inc.

      This Alliance
Agreement (“Agreement”) is entered into on this 3rd day of 2008 by and between Labwire, Inc. (hereinafter “Labwire”), and
USIS Commercial Services, Inc., (hereinafter “USIS”).

       

      WHEREAS USIS
provides certain pre-employment background screening products and services and
drug/alcohol testing services to end user customers all of which are hereafter
referred to, both singularly and collectively, as the “USIS Services” and USIS
maintains a Web site at www.usis.com (which site and any successor sites shall
be referred to as the “USIS Site'); and

       

      WHEREAS Labwire
provides certain automated drug testing program management services and related
products referred to, both singularly and collectively, as the “DAT Services*
and maintains a Web site at www.labwire.com (which site and any successor or
affiliated sites shall be referred to as the “Labwire Site”); and

       

      WHEREAS USIS
desires to promote Labwire as a preferred provider of DAT Services to certain
specific customers; and

       

      WHEREAS Labwire
desires to provide incentives to USIS for the referral of Customers and the
resulting revenues from such Referral Customers; and

       

      NOW, THEREFORE,
Labwire and USIS, in consideration of the mutual promises and undertakings
herein recited and intending to be legally bound, agree as follows:

       

      1.    
Definitions. For purposes of this Agreement, the following definitions
will apply:

       

      a.     
“Referral Customers” will mean the direct end-user clients of USIS who purchase
USIS Services directly from USIS including DAT Services performed by Labwire and
are referred by USIS to the DAT Services offered by Labwire.

       

      b.    
“Service Agreements” will mean executed contracts between USIS and Referral
Customers under which USIS agrees to provide USIS Services including DAT
Services performed by Labwire and deliver said products and services.

       

      c.     
“USIS Services” will mean the products and/or services directly provided by USIS
to its end users under separate USIS Service Agreements and may include DAT
Services provided by Labwire.

       

      d.    
“DAT Services” will mean the drug testing products and/or services provided by
Labwire under the TPA Agreement between USIS and Labwire.

       

      e.     
“Commission” will mean the percentage of Revenue due to USIS for DAT Services
provided by Labwire as TPA for Referral Customers to Labwire under this
Agreement.

       

      f.     
“Revenue” will mean the flat price charged to the Referral Customer for DAT
Services times the number of tests in the billing cycle.

       

      2.     Term. The term of this
Agreement will commence on the date first set forth above and will continue in
effect for an initial term of two (2) years, unless earlier terminated pursuant
to the terms and conditions of this Agreement.

       

      3.     Responsibilities of USIS. USIS
agrees to perform the following responsibilities in connection with this
Agreement

       

      a.    
Subject to the terms and conditions of this Agreement, ail determinations
concerning the terms and conditions of USIS Services offered to its customers,
will be made by USIS.

       

      b.    
USIS will be responsible to provide USIS Services in accordance with the
executed Service Agreements that USIS obtains with its customers.

       

      c.    
On a non-exclusive basis, USIS will promote Labwire as a recommended and
preferred provider of DAT Services in exchange for tile Commission payments
provided in Section 7 of this Agreement.

       

      d.    
USIS will advise Labwire of the prospective Referral Customer using the Referral
Form attached to this Agreement as Exhibit A.

       

      4.    
Responsibilities of Labwire. Labwire agrees to perform the following
responsibilities in connection with this Agreement.

       

      a.     
Labwire will provide DAT Services under the TPA Agreement with USIS.

       

      b.    
Labwire will not make any representations, warranties, or commitments relative
to USIS Services or negotiate any USIS contract terms, conditions or
prices.

       

      c.     
Labwire will pay Commissions to USIS for Referral Customers in accordance with
the provisions of Section 7 of this Agreement.

       

      5.       
Expenses. Except
as otherwise set forth in this Agreement, each party will be individually and
solely liable for its own costs under this Agreement.

       

      6.       
Billing and Collection.
USIS will perform all billing and collection functions with regard to
orders placed by Referral Customers. All orders for USIS Services will be placed
directly with USIS by Referral Customers and USIS will pay Labwire for relevant
DAT Services provided under the terms of the TPA Agreement Labwire shall invoice
USIS for DAT Services provided under the terms of the TPA Agreement and USIS
shall pay such invoices for DAT Services directly to Labwire. Such payments from
USIS to Labwire shall be discounted by the Commission percentage specified in
Section 7 of this Agreement.

       

      7.       
Commissions on Referral
Customers. Unless otherwise agreed by the parties hereto in writing,
Labwire agrees that USIS shall be entitled to the Commission percentage of ten
percent (10%) of Revenue received from Referral Customers. Revenue shall be
defined as the flat price charged to the Referral Customer for DAT Services
times the number of tests in the billing cycle. Any proposed change to the flat
price charged to the Referral Customer for DAT Services under this Agreement
will be reviewed and approved by both parties. Referral Commissions are subject
to the following terms and conditions:

       

      a.     
Referral Customers shall be submitted to Labwire using the Customer Referral
Form document provided in Exhibit A for each Referral Customer. USIS and Labwire
shall follow the process defined in Exhibit A for submitting and qualifying
prospective leads.

       

      b.    
Commissions wit) be deemed earned only when all of the following criteria are
fulfilled:

       

      i.
The Referral Customer and USIS have entered into an agreement for the provision
of USIS Services including DAT Services within one hundred eighty (180) days of
the referral date (“Referral Date”) reflected in the specific Customer Referral
Form tor the prospective customer's purchase of products duly executed by both
parties to the contract. Commissions win be paid on the initial and alt
subsequent orders for the term of the contract between USIS and the Referral
Customer even if this Agreement terminates or expires.

       

      ii.
The DAT Services have been delivered to and paid for by the Referral Customer to
USIS. USIS must employ reasonable commercial efforts to collect from delinquent
Referral Customer accounts. Commission will not be paid on bad debts or amounts
deemed by USIS to be uncollectible or for DAT Services not meeting the standards
set forth in the TPA Agreement between USIS and Labwire.

       

      c.     
Unless otherwise agreed in writing, Commissions will be reported to and payable
to USIS thirty (30) days after the end of the month in which the Commission is
earned. The parties may agree to alternative methods for receiving compensation
for Commissions and any such alternative payment methods shall be specified and
agreed on the Customer Referral Form document provided in Exhibit A.

       

      d.    
Labwire agrees that it shall not knowingly solicit any USIS Customer. For
purposes of this provision, solicitation includes without limitation, responding
to Requests for Proposals, (RFP's), and direct or indirect sales calls that
would result in direct competition for the provision of any USIS Services
currently under direct contract between such USIS Customer and USIS. This
provision specifically includes FirstGroup America and all of its affiliates,
agents, subsidiaries, parents, successors, and assigns.

       

      e.     
If this Agreement is terminated, USIS will be entitled to continue to receive
Commissions on qualified and accepted Referral Customers which were submitted to
Labwire prior to the date of termination, or within thirty (30) days after such
date of termination.

       

      f.     
USIS may in its sole discretion discontinue USIS Services for any Referral
Customer if it reasonably determines that continued services to such Customer
(1) would be detrimental to USIS's business (i.e.: such customer is a
competitor, or has bad credit); or (2) would violate certain restrictions
defined by USIS company policies for qualifying new customers; or, (3) would
violate federal, state, or local taws; or (4) would violate USIS's contractual
obligations with other parties such as government agencies or data
suppliers.

       

      g.    
Both parties shall keep full and accurate records related to Referral Customers
to enable accurate reporting of the commissions earned by USIS each month. Both
parties shall have the right, upon reasonable prior written notice, to audit the
books, records and accounts of the other relating to the Referral Customers and
Commissions paid or due under this Agreement. The expenses of such audits shall
be borne by the auditing party. Audits shall be limited to records specifically
related to this Agreement. Audits shall occur no more often than three (3) times
per calendar year and no more often man two (2) times per any quarter.

       

      h.    
Labwire will comply with reasonable procedures and guidelines established by
USIS for the use of consumer information and will comply by all applicable
federal, state, and local laws and regulations. USIS has the right to require
reasonable evidence of Labwire's compliance with applicable laws and USIS's
guidelines for use of consumer information products.

       

      i.     
Any violations discovered as a result of such audits may be cause for immediate
action by either party, including but not limited to, termination of this
Agreement.

       

      8. Indemnification.

       

      a.    
Labwire will indemnify and hold USIS harmless from and against any and all third
party claims and liabilities resulting therefrom, together with reasonable
attorney's fees and costs incurred in connection therewith, resulting
from:  (a) any unauthorized representations, warranties or commitments made
by Labwire with respect to the USIS Services; or (b) any breach by Labwire of
its obligations under this Agreement; or (c) Labwire's violation of applicable
laws.

       

      b.    
Except for liabilities for which Labwire owes USIS an indemnification obligation
as stated in 8(a), USIS will indemnify and hold Labwire harmless from and
against any and all third party claims and liabilities resulting therefrom,
together with reasonable attorney's fees and costs incurred in connection
therewith, resulting from (1) any provision of USIS Services to any Referral
Customer (2) breach by USIS of its obligations under this Agreement; or (3)
USIS's violation of applicable laws.

       

      c.    
A party's duty to indemnify the other under this Agreement is conditional on:
(a) the party seeking indemnification providing the indemnifying party with
prompt notice of any claim, demand, action, liability, suit or damage for which
indemnification is sought; and (b) the party seeking indemnification affording
the indemnifying party with the opportunity to handle the defense of the matter
for which indemnification is sought.

       

      9. LIMITATION OF LIABILITY IN
NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL,
INCIDENTAL OR PUNITIVE DAMAGES, OR FOR ANY LOST PROFITS OF ANY KIND, EVEN IF
SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS.

       

      10. Termination.

       

      a.    
Either party will have the right to terminate this Agreement at any time upon
ninety (90) days advance written notice.  Either party will have the right
to terminate this Agreement for Good Cause upon ten (10) days advance written
notice, unless the other party cures the material breach stated for termination
in such notice within ten (10) days of its receipt of such notice. “Good cause”
will include, but not necessarily be limited to: (i) material breach of this
Agreement by the other party; or (ii) the termination or suspension of business
by the other party; or (iii) insolvency of the other party; or (iv) the other
party becoming subject to bankruptcy or insolvency proceedings or to direct
control by a trustee, receiver or similar authority. Good cause will also
include modification by USIS of its distribution methods or discontinuance of
the sale of the USIS Services or the DAT Services, in which event this Agreement
with be terminated upon ninety (90) days written notice by USIS to
Labwire.

       

      b.    
Termination of this Agreement will not constitute a waiver of any rights or
remedies at law or in equity.

       

      c.    
Upon termination of this Agreement, all pre-existing Referral Customer Service
Agreements will remain in effect with USIS per their terms. All obligations to
pay Referral Commissions that were incurred prior to any termination of this
Agreement shall survive termination of the Agreement.

       

      d.    
Termination of this agreement becomes effective upon discontinued integration
and services accessed through integration notwithstanding the written notice
provisions in Section 10.a above. Referral Commissions that were incurred during
the integration shall survive termination of the Agreement and the
discontinuation of the integration.

       

      e.    
The obligation to pay commissions to USIS shall survive the expiration or
earlier termination of this Agreement

       

      11.    Confidential Information.
Proprietary or confidential information disclosed by the parties, including but
not limited to the existence and the terms of this Agreement, technological
information about weir respective Web sites, business plans, financial
information, customer information, and pricing and sates information
(“Confidential Information”) shall not be disclosed to any third party, other
than to employees, agents, and consultants who need to know such Confidential
Information and who shall be advised they are subject to these restrictions
regarding Confidential Information. Recipient shall be responsible for any
wrongful disclosure of Confidential Information made by any third party to whom
Recipient revealed the Confidential Information, The foregoing obligations shall
not apply with respect to any Confidential Information that (a) is or becomes
publicly known through no wrongful act or omission of Recipient; (b) was
rightfully known by Recipient before receipt from the disclosing party; (c)
becomes rightfully known to Recipient without confidential or proprietary
restriction from a source which does not owe a duty of confidentiality; or (d)
is independently developed by Recipient without the use of, or reference to, the
Confidential Information.  Recipient may disclose Confidential Information
to the extent disclosure is required by law or court order; provided, however,
that to the extent possible, prior to any such compelled disclosure, Recipient
shall give the disclosing party reasonable advance notice of any such disclosure
so the disclosing party
has an opportunity to lawfully prevent or limit the scope of such disclosure.
This Section shall survive the termination of this Agreement

       

      12.    Relationship of the Parties.
The relationship established by this Agreement is that of independent
contractors. No partnership, employment, franchise, reseller, joint-venture or
such other relationship is established by this Agreement neither party has the
authority to incur obligations on behalf of the other; and, no community of
interest is established among the parties by this Agreement. Although the
parties hereto will collaborate to introduce new Customers to each other, each
party will conduct its respective business at its own initiative, responsibility
and expense.

       

      13.    General.

       

      a.     Agreement
Modification. Except as expressly allowed herein, the terms of this
Agreement may only be modified or waived by written agreement of both parties.
Any waiver of any of the terms provided for herein is only for the particular
matters specified and will not constitute a waiver of any of the other terms of
this Agreement, nor will waiver of a provision in one instance prevent
enforcement of that provision on any other occasion. USIS may, at any time and
at its sole discretion, and with at least 30 days prior written notice to
Labwire, discontinue any of the USIS Services, change the terms and conditions
of its product and service agreements, and change service and product literature
and any other service and product sales aids. Such changes will not affect
current Customer agreements except to the extent permitted in such
agreements.

       

      b.     Force
Majeure. Neither party will be liable in the event that its performance
of this Agreement is prevented, or rendered so difficult or expensive as to be
commercially impracticable, by reason of an Act of God, labor dispute,
unavailability of transportation, goods or services, governmental restrictions
or actions, war (declared or undeclared), or other hostilities, or by any other
event, condition or cause which is not foreseeable on the date of this Agreement
and is beyond the reasonable control of the party. It is expressly agreed that
any failure of the United States Government to issue a required license for the
export of any USIS Product ordered by Labwire hereunder will constitute an event
of force majeure. In the event of non-performance or delay in performance
attributable to any such causes, the period allowed for performance of the
applicable obligation hereunder will be extended for a period equal to the
period of the delay. However, the party so delayed will use its best efforts,
without obligation to expend substantial amounts not otherwise required under
this Agreement to remove or overcome the cause of delay. In the event that the
performance of a party is delayed for more than six (6) months, the other party
will have the right, which will be exercisable for so long as the cause of such
delay will continue to exist, to terminate this Agreement without liability for
such termination.

       

      c.    
Assignment  Neither party may assign this Agreement nor subcontract
or delegate its responsibilities without the express written consent of the
other whose consent shall not be unreasonably withheld. Any such assignment or
subcontract will be void and will constitute a material breach and default under
this Agreement

       

      d.    
Notice. Except as otherwise specified herein, any notice to be given
under the terms of this Agreement will be in writing and will be either hand
delivered or sent by overnight courier or United States mail, postage and
delivery prepaid, to the parties at the addresses specified in this Agreement,
or such other location as the other parties may provide each other from time to
time by written notice. Notice will be deemed effective upon delivery.

       

      e.     
Governing Law. This Agreement will in all respects be governed by, and
enforced and interpreted in accordance with, the laws of the State of Oklahoma,
except with respect to its rules relating to conflicts of laws.

       

      f.     
Severability. In the event that one or more of the provisions contained
in this Agreement will for any reason be held to be invalid, illegal or
unenforceable in any respect, this Agreement will be enforced to the maximum
extent possible.

       

      g.     Third
Party Beneficiaries. There are no third party beneficiaries to the
Agreement.

       

      h.     Use of the
Parties' Names, Trademarks. Each party acknowledges and agrees that it
neither acquires nor can it convey any right title or interest in and to the
other party's trademarks, services marks, trade names, logos, copyrights,
intellectual property rights or any other asset used to identify and distinguish
tile other party's goods, services or business, as they exist today and as they
may be amended or expanded in the future, all of which shall be collectively
referred to herein as the “Marks” Each party must review and approve in writing,
prior to use or publication, any and all use of its Marks on the Internet and
all activities or communications that reference or use the Marks. Each party
hereby grants the other a non-exclusive, non-transferable, limited license to
reproduce, display and use its Marks solely to provide the Services. Upon
termination of this Agreement each party shall immediately discontinue the use
of the other's Marks.

       

      i.     
Merger/Amendment. This Agreement constitutes the entire agreement between
the parties with respect to the subject matter hereof. There are no
understandings or agreements, express or implied, not specified herein, and the
foregoing terms and conditions will prevail, notwithstanding any variance with
the terms and conditions of any documentation, order or other written materials
submitted by Labwire with respect to this matter. This Agreement will not be
deemed or construed to be modified, amended, rescinded, canceled or waived in
whole or in part, except by written amendment by the parties hereto.

       

      Each Party represents
that the Agreement has been executed on such Party's behalf on the date written
below by a representative authorized to bind that Party with respect to the
undertakings and obligations contained in the Agreement

       

      
        
          

        

        
          USIS
Commercial Services,
Inc.                                                                 Labwire,
Inc.

        

        
          

        

        
          By: //s// Tim M.
Willis                                                                                   By:
//s// G. Dexter
Morris

        

               (Authorized
Signature)                                                                                   (Authorized
Signature)

        

        Tim M. Willis, VP
Director                                                                                   G. Dexter
Morris

        
          Print
Name/Title                                                                                           Print
Name/Title

        

        
          

        

        
          Address:  4500
S. 129th E. Ave.
Suite 200                        Address: 14133
Memorial Drive Suite 1

        

        
                  Tulsa,
OK  74134-5885                                                              Houston,
TX 77079

        

        
          Phone: 918-664-9991                                                                            Phone:
281-597-1611ex103.htm

    
      
        
          
            EXHIBIT
10.03

          

          
            Master
Service Agreement with Laboratory Corporation of America
Holdings

          

          
            

          

          
            MASTER
SERVICES AGREEMENT

          

          
            
              AGREEMENT
MADE THIS  22   day
of  January   ,
2004 by and between Workplace Screening Services of  Houston.
TX  , an   LLC      corporation
(“CLIENT”) and Laboratory Corporation of America Holdings and its
subsidiaries (“COMPANY”).

            

            
              

            

            
              WHEREAS,
COMPANY is engaged in the business of providing a variety of occupational
services as more specifically described in Exhibit A (“Services”);
and

            

            
              

            

            
              WHEREAS,
CLIENT desires to contract with COMPANY to provide the Services; and FT IS
THEREFORE AGREED AS FOLLOWS:

            

            
              

            

            
              1. TERM

            

            
              This
Agreement shall become effective  February 1 , 2004 and shall
continue in effect until terminated by either party. This Agreement shall
have an initial term of one (1) year (“Initial Term”) and shall be automatically
renewed subject to price changes for additional period of one (1) year (“Renewal
Term”) at the end of the Initial Term or any Renewal Term, unless previously
terminated by either party. This Agreement may also be immediately terminated by
either party if the other party breaches or fails to perform any of its
obligations in any material respect, attempts to assign its rights under this
Agreement or if the other party becomes insolvent or proceedings are instituted
by or against it under any provision of any federal or state bankruptcy or
insolvency laws.

            

            
              

            

            
              This
Agreement may be terminated by either party, with or without cause, at any time,
by giving the other party a thirty (30) day prior written
notice.

            

            
              

            

            
              2. SERVICES

            

            
              COMPANY
shall perform or arrange for the Services as set forth in Exhibit A. CLIENT
acknowledges and agrees that the Services provided for under this Agreement
shall be for COMPANY'S occupational testing services only and shall not include
any clinical laboratory testing services which are specifically excluded from
this Agreement. Services shall be provided utilizing applicable federal, state
and/or COMPANY'S standard testing guidelines and procedures.

            

            
              

            

            
              3. ON-SITE
TESTING PRODUCTS

            

            
              As
requested by CLIENT from time to time for its on-site drug screening programs,
COMPANY will provide the products and Services shown in Exhibit A, including the
Point of Collection Testing (“POCT Products”) manufactured by third party
companies.

            

            
              

            

            
              CLIENT
acknowledges and understands that the group of POCT Products available under
this Agreement may not be approved for use in certain state or federally
regulated workplace programs. In all cases of CLIENT'S on-site testing, it shall
be the sole responsibility of CLIENT to ensure that the POCT Products are used
in accordance with all applicable state and federal laws and regulations. CLIENT
warrants and represents that its use of POCT Products shall be solely for
forensic/workplace purposes only. In addition, the POCT Products used for the
screening test and any confirmation tests performed on presumptive positive
screens are not intended for diagnostic purposes. CLIENT shall ensure that all
its facilities performing on-site testing with the POCT Products have and
maintain all appropriate and required licenses. Furthermore, once purchased by
CLIENT, POCT Products are not returnable.

            

            
              

            

            
              CLIENT
ACKNOWLEDGES THAT THE ONLY WARRANTY PROVIDED FOR THE POCT PRODUCTS ARE THOSE
PROVIDED BY THE MANUFACTURER AND THE POCT PRODUCTS ARE PROVIDED “AS IS”. NO
WARRANTIES ARE MADE BY COMPANY WITH RESPECT TO SUCH POCT
PRODUCTS.

            

            
              

            

            
              CLIENT
RECOGNIZES THAT COMPANY SHALL HAVE NO LIABILITY FOR THE PERFORMANCE OR DAMAGE OR
INJURY CAUSED BY THE USE OF SUCH POCT PRODUCTS.

            

            
              

            

            
              13. WARRANTY

            

            
              
                	
                        (A)  
      

                      	
                        CLIENT
      WARRANTS TO COMPANY THAT NEITHER CLIENT NOR TO THE BEST OF ITS KNOWLEDGE
      ANY OF ITS EMPLOYEES OR OWNERS HAVE BEEN DEBARRED, SUSPENDED, DECLARED
      INELIGIBLE, OR EXCLUDED FROM ANY GOVERNMENTAL PROGRAM. COMPANY WARRANTS TO
      CLIENT THAT ALL LABORATORY SERVICES THAT IT PROVIDES DIRECTLY HEREUNDER
      SHALL BE PERFORMED IN ACCORDANCE WITH ESTABLISHED AND RECOGNIZED
      ANALYTICAL LABORATORY TESTING PROCEDURES WHERE APPLICABLE, AND WITH
      REASONABLE CARE IN ACCORDANCE WTTH APPLICABLE FEDERAL, STATE, AND LOCAL
      LAWS. NO OTHER WARRANTIES ARE MADE BY
COMPANY.

                      

              

            

            
              

            

            
              
                	
                        (B)  
      

                      	
                        IN
      NO EVENT SHALL COMPANY BE RESPONSIBLE FOR ANY PUNITIVE DAMAGES OR ANY
      CONSEQUENTIAL, INCIDENTAL, INDIRECT, OR SPECIAL DAMAGES (INCLUDING LOST
      PROFITS OR REVENUE) OF CLIENT OR ANY THIRD
  PARTY.

                      

              

            

            
              

            

            
              
                	
                        (C)  
      

                      	
                        CLIENT
      FURTHER WARRANTS AND REPRESENTS THAT IT WILL NOT BILL OR SEEK COMPENSATION
      FROM MEDICARE, MEDICAID OR ANY OTHER GOVERNMENT PAYOR FOR THE SERVICES
      PROVIDED HEREIN. CLIENT WARRANTS AND REPRESENTS THAT ITS CUSTOMERS
      UTILIZING SERVICES UNDER THIS AGREEMENT ARE ALL ENTITIES WHO SHALL PAY
      CLIENT DIRECTLY FOR THE SERVICES PROVIDED HEREIN WITH THEIR OWN
      FUNDS.

                      

              

            

            
              

            

            
              14. INDEMNIFICATION

            

            
              COMPANY
agrees to defend, indemnify, and hold CLIENT, its parent, subsidiaries,
affiliated and related companies, directors, officers, employees, and agents
wholly harmless from and against all third party claims, losses, lawsuits,
settlements, demands, causes, judgments, expenses, and costs (including
reasonable attorney fees) arising under or in connection with this Agreement to
the extent that such costs and liabilities are proximately caused by the
negligence or willful misconduct of COMPANY in directly performing services
hereunder.

            

            
              

            

            
              CLIENT
agrees to defend, indemnify, and hold COMPANY, its parent, subsidiaries,
affiliated and related companies, directors, officers, employees, and agents,
wholly harmless from and against all third party claims, losses, lawsuits,
settlements, demands, causes, judgments, expenses, and costs (including
reasonable attorney fees) arising under or in connection with this Agreement to
the extent that such costs and liabilities are proximately caused by the
negligence or willful misconduct of CLIENT or any violation of applicable laws
and regulations.

            

            
              

            

            
              15. CONFIDENTIAL
INDIVIDUAL INFORMATION

            

            
              To the
extent consistent with 5 U.S.C. 552a(m) and 48 C.F.R. 24.101-24.104 and other
applicable laws and regulations, the parties shall comply with the Privacy Act,
5 U.S.C. 552a and patient access and confidentiality provisions of Section 503
of Pub.L 100-71. Individual records shall be maintained and used with the
highest regard for privacy, and to the extent applicable as provided in 10
C.F.R. 26.29.

            

            
              

            

            
              16. BENEFIT

            

            
              This
Agreement is intended to inure only to the benefit of COMPANY and CLIENT. This
Agreement is not intended to create, nor shall be deemed or construed to create,
any rights in any third parties.

            

            
              

            

            
              17. NONDISCRIMINATION

            

            
              All
services provided by COMPANY hereunder shall be in compliance with all
applicable Federal and State laws prohibiting discrimination on the basis of
race, color, religion, sex, national origin, disability or veteran
status.

            

            
              

            

            
              18. ENFORCEABILTTY/SEVERANCE
CLAUSE

            

            
              The
invalidity or unenforceability of any terms or provisions hereto in any
jurisdiction shall in no way affect the validity or enforceability of any of the
other terms or provisions in that jurisdiction, or of the entire Agreement in
any other jurisdiction.

            

            
              

            

            
              19. INTEGRATION

            

            
              This
instrument is intended by the parties as a final expression of their agreement
regarding the Services herein and as a complete statement of the terms thereof,
and shall supersede all previous understandings and agreements regarding the
subject matter herein. The parties shall not be bound by any representation,
promise, or inducement made by either party or agent of either party that is not
set forth in this Agreement. If the terms or conditions contained in any exhibit
or attachment to this Agreement or any document incorporated by reference is in
conflict with the terms and conditions set forth in the body of this Agreement,
the terms and conditions in this Agreement shall control. Any applicable
provisions required by federal, state, or local law are hereby incorporated by
reference.

            

            
              

            

            
              20. MODIFICATION

            

            
              This
Agreement may not be modified except in a writing signed by authorized
representatives of both parties. Any purchase order or other document issued by
CLIENT with respect to the subject matter of this Agreement shall be subject to
and governed by the terms and conditions hereof, and the terms and conditions of
this Agreement shall supersede any conflicting, different, or additional terms
and conditions of such purchase order or other document.

            

            
              

            

            
              IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed in their
names as their official acts by their respective representative, each of whom is
duly authorized to execute the same.

            

          

           

           

          
            
              Workplace
Screening Services

            

            
              

            

            
              By:                                                     

            

            
                    President

            

            
               

               

              
 

            

            
              Laboratory
Corporation of America

            

            
              

            

            
              By:                                                     

            

            
              Title:                                                     

            

            
              Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]